Dyax enjoys climbing stock prices

Dyax had a great day Monday. The company released positive late-stage clinical trial findings regarding its drug DX-88 and investors took notice. According to its data, DX-88 reduced the symptoms associated with hereditary angioedema, a genetic blood disorder, and stocks climbed by 15.5 percent, to the company's 2008 peak thus far.  Report